Mirzaten Oro Tab (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes 5‑HT2 and 5‑HT3 serotonin receptors. This dual action boosts overall serotonergic and noradrenergic activity, helping to improve mood and alleviate depressive symptoms.

The specific dose is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Typical starting doses are low and may be adjusted gradually, but exact regimens should only be set by a qualified health professional.

Safety data for mirtazapine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs that primarily inhibit serotonin reuptake. Its receptor profile often results in stronger sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about these side effects.

Store tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Mirzaten Oro Tab is taken orally, usually once daily in the evening. Swallow the tablet whole with a glass of water; it may be taken with or without food, but consistent timing helps maintain stable blood levels.

Serious risks include agranulocytosis or severe leukopenia, seizures, hypersensitivity reactions such as Stevens‑Johnson syndrome, worsening depression or suicidal thoughts, and serotonin syndrome when combined with other serotonergic drugs. Immediate medical attention is required if any of these occur.

Mirtazapine is contraindicated in patients with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or individuals with severe hepatic impairment where dose adjustment is not feasible. Caution is also advised for patients with a history of bipolar disorder who may switch to mania without proper monitoring.